A GLP-1 receptor agonist approved for type 2 diabetes and chronic weight management.
AIMS: The objective of this analysis was to identify the 6-month discontinuation rate for GLP-1 analogues, reasons for discontinuation, and characteristics associated with discontinuation. MATERIALS AND METHODS: This was a retrospective analysis of a…
Despite the cardiometabolic benefit of semaglutide, its impact on quality of life and whether patients' characteristics influence clinical outcomes and health-related quality of life (HRQoL) remain ambiguous.A retrospective review of patient charts w…
BACKGROUND: Diabetic nephropathy (DN) is a major microvascular complication of type 2 diabetes and a leading cause of end-stage renal disease. Both canagliflozin and semaglutide are recommended for diabetic nephropathy, yet direct evidence comparing…
Incretin therapies have emerged as key interventions for glycemic control and weight reduction and are now among Canada's costliest outpatient drug classes. This review synthesizes current clinical and economic evidence on the cost-effectiveness of i…
This case study reviews the use of glucagon-like peptide-1 receptor agonists (GLP-1 RA) for weight management in older adults. A 69-year-old male patient discusses weight loss goals with his health care provider and seeks pharmacotherapy options in a…
Pulmonary delivery provides a noninvasive route for systemic administration of biologics, yet efficient lung deposition and permeation across pulmonary barriers remain major challenges. In this study, morphology-engineered zinc oxide (ZO) biointeract…
BACKGROUND: Obesity is a worldwide health concern linked to cardiometabolic comorbidities such as type 2 diabetes, hypertension, dyslipidemia, and heart disease. The management of obesity using pharmacotherapy, especially with GLP-1 receptor agonists…
A 58-year-old man scheduled for an elective upper endoscopy followed standard preprocedural fasting guidelines and withheld one weekly dose of semaglutide, a glucagon-like peptide-1 (GLP-1) receptor agonist (GLP-1 RA). Despite these measures, substan…
Cardiovascular outcome trials of the incretin-based medicines tirzepatide and semaglutide have shown benefits in populations with varying levels of cardiovascular risk. However, without direct head-to-head comparisons, treatment decisions rely on ind…
INTRODUCTION: Semaglutide has gained attention for its efficacy in weight loss. However, little is known about patients' experiences. This study explores patient experiences with using Semaglutide for weight loss (SEMA-WL) in a rural Danish context.…
Metabolic dysfunction-associated steatotic liver disease (MASLD), the hepatic manifestation of metabolic syndrome, has emerged as the leading cause of chronic liver disease worldwide. Its global prevalence estimated at 38% between 2016-2019, represen…
BACKGROUND: Semaglutide, a glucagon-like peptide-1 receptor agonist, is increasingly used for obesity and type 2 diabetes treatment. As its use rises among women of reproductive age, understanding its impact on fetal and neonatal health is essential.…
AIMS: Treatment of obesity with glucagon-like peptide-1 (GLP-1) receptor agonists improves cardiovascular outcomes. Tirzepatide, a dual glucose-dependent insulinotropic polypeptide and GLP-1 receptor agonist, achieves greater weight loss than GLP-1 r…
BACKGROUND: Cardiac microvascular injury from hyperlipidaemia and hyperglycaemia is associated with increased major adverse cardiovascular events (MACE). Semaglutide, a long-acting GLP-1 receptor agonist, reduces diabetic cardiovascular complications…
Semaglutide is an anti-obesity and anti-diabetic drug used in long-term weight management and for the treatment of type 2 diabetes. A toxicology study was conducted on a generic synthetic version of Semaglutide Injection (2 mg/3 mL) produced by Bioco…
Marine macroalgae are increasingly recognized as sources of bioactive compounds with potential benefits for metabolic health. This study investigated the chemical composition and metabolic effects of a 70% ethanol extract of the edible red algain a h…
Aim To evaluate the dynamic impact of an 8-month glucagon-like peptide-1 receptor agonist (GLP-1 RA) therapy with semaglutide on anthropometric metrics, blood lipid profiles, and adipokine status in obese patients, with and without type 2 diab…
OBJECTIVE: Two glucagon-like peptide-1 receptor agonists (GLP-1 RAs) (semaglutide and liraglutide) and one dual agonist (tirzepatide) are FDA-approved for weight loss in adults with obesity without type 2 diabetes mellitus. This systematic review and…
BACKGROUND: Laboratory changes after antiobesity drugs in routine care are not well-described. STUDY QUESTION: In adults with obesity and no diabetes, how do 2-year laboratory trends and major clinical outcomes compare after starting semaglutide vers…
In 2025, nephrology saw major advances in diagnosing and managing chronic kidney diseases. A new diagnostic framework, CKDx (chronic kidney disease of unexplained cause), was proposed to standardize patient evaluation by integrating genetic and histo…